These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34782206)

  • 1. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lövgren K; Marzouka NA; Olsson H; Höglund M; Ullén A; Liedberg F
    Eur Urol; 2022 May; 81(5):523-532. PubMed ID: 34782206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
    Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
    Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
    Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.
    Holmsten K; Sjödahl G; Abrahamsson J; Bernardo C; Eriksson P; Höglund M; Liedberg F; Ullén A
    JCO Precis Oncol; 2024 Oct; 8():e2400209. PubMed ID: 39348658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment.
    Ecke TH; Voß PC; Schlomm T; Rabien A; Friedersdorff F; Barski D; Otto T; Waldner M; Veltrup E; Linden F; Hake R; Eidt S; Roggisch J; Heidenreich A; Rieger C; Kastner L; Hallmann S; Koch S; Wirtz RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
    Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
    Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
    Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
    Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
    Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
    Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Necchi A; de Jong JJ; Raggi D; Briganti A; Marandino L; Gallina A; Bandini M; Dabbas B; Davicioni E; Capitanio U; Montorsi F; Seiler R; Wright JL; Lotan Y; Black PC; Gibb EA
    Eur Urol; 2021 Aug; 80(2):149-159. PubMed ID: 33785257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
    Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
    Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.